Welcoming the NHS 10-Year Plan

Welcoming the NHS 10-Year Plan

Copenhagen, Denmark 

On July 3rd 2025, the UK Government published Fit for the Future: 10 Year Health Plan for England, outlining a bold, transformative vision to make the NHS sustainable, equitable, and technology-led for the next decade and beyond.

This plan hinges on three radical shifts:

  1. From hospital to community
  2. From analogue to digital
  3. From sickness to prevention

It emphasizes empowering patients, deploying predictive and preventive care, embracing wearables and AI, integrating care teams locally, and making NHS staff more effective and supported.

Monsenso celebrates these ambitions, and stands ready to support the NHS in delivering them.

How Monsenso Aligns with the NHS Vision

Hospital → Community: Local, continuous, personalised mental health support

The NHS aims to shift care into neighbourhood health centres and patients’ homes, creating continuous, integrated care pathways.

Monsenso’s digital health platform enables precisely this shift into remote patient monitoring. By combining self-reported symptom data with wearable sensor data, our system allows clinicians to monitor mental health remotely, detect early signs of deterioration, and intervene proactively, without waiting for hospital referrals.

Analogue → Digital: Empowered patients and data-driven care 

With the NHS committed to digital transformation, turning the NHS App into a full “front door”, Monsenso offers a complementary digital health tool that seamlessly integrates into clinicians’ workflows while putting patients in control of their day-to-day mental health management .

Our mobile apps support:

  • Electronic patient-reported outcomes (e-PROs)
  • Medication and appointment reminders
  • Psychoeducational content and self-help tools
  • Secure two-way messaging between patients and care teams

Clinicians gain access to actionable dashboards, analytics and predictive risk alerts; all in the cloud, accessible anytime, anywhere.

Sickness → Prevention: Early detection, digital prevention, value-based care

The NHS plan emphasises predictive care, with wearables becoming standard, and incentives for preventive interventions & value-based outcomes .

Monsenso supports predictive analytics and mood forecasting, drawing on real-world behavioural data to flag rising risk and support earlier intervention before crisis points. Campaigns like the ECoWeB CBT-based app trials – built on Monsenso’s platform – have demonstrated that sustained self-help interventions can prevent depression onset in high-risk youth across several countries. This aligns with the NHS’s focus on prevention, mental wellbeing in young people, and cost-effective scaling.

Supporting workforce, transparency & innovation

The NHS wants a workforce empowered through digital tools, and more transparency using patient-reported outcome measures and performance data. By providing clinicians with real-time insights into engagement, adherence, symptoms and outcomes, Monsenso reduces administrative burden, enables triage based on clinical risk, and supports shared decision-making with patients.

As a CE and UKCA-marked medical device, certified to ISO 27001, ISO 13485 and Cyber Essentials, Monsenso meets the UK and EU regulatory and digital compliance standards, and is ready to integrate within NHS quality, safety, and innovation frameworks.

Key Benefits for NHS Mental Health Services

NHS Priority Area How Monsenso Helps
Community-based care Enables remote monitoring, blended care and integration across primary, secondary and community settings
Digital access  A digital companion that could be aligned with NHS App ‘HealthStore’ pathways and services
Preventive mental health Predictive analytics, self-help interventions, early risk detection, and prevention of relapse or crisis
Patient empowerment & equity Inclusive tools for self-management, carers and diverse populations; scalable across regions
Workforce productivity Streamlines patient review, prioritises high-risk cases, reduces admin burden, freeing clinicians for care.

 

Championing Change with Monsenso

At Monsenso, our mission is to make mental healthcare more predictive, equitable, person-centred, and scalable – perfectly aligned with the NHS 10-Year Plan. Our digital health platform is already in use in multiple countries, supporting thousands of individuals living with conditions such as depression, bipolar disorder, anxiety, schizophrenia, and addiction. With high adherence rates and robust real-world evidence from research partnerships, we know digital tools can work at scale.

We’re ready to collaborate with NHS England, integrated care boards, neighbourhood health centres and mental health providers to deliver against key NHS targets – especially for youth mental health, the expansion of mental health in primary care and remote psychological support.

Looking Ahead

As the NHS embarks on its most transformative decade, Monsenso is poised to partner where technology, data-driven care and human-centred health practice converge. We look forward to supporting the NHS to make mental and somatic health support more accessible, effective and forward-looking – together.


To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Monsenso successfully completes ISO 13485 re-certification audit

Monsenso successfully completes ISO 13485 re-certification audit

Copenhagen, Denmark 

Monsenso is proud to announce the successful completion of its ISO 13485 re-certification audit, reaffirming our commitment to the highest standards of quality and safety in the development of digital health solutions for mental health.

ISO 13485 is the internationally recognised gold standard for medical device companies, ensuring that products consistently meet customer requirements, regulatory expectations, and the highest levels of safety and efficacy. The re-certification confirms that Monsenso’s Quality Management System (QMS) continues to meet stringent requirements specific to the medical device industry.

“Ensuring quality and compliance is at the heart of what we do. Our ISO 13485 re-certification underscores our dedication to delivering safe, effective, and reliable solutions that healthcare providers and patients can trust,” says Thomas Lethenborg, CEO at Monsenso.

This achievement reflects Monsenso’s ongoing efforts to provide secure, clinically validated mobile health solutions that empower patients, support clinicians, and strengthen health services worldwide.

For additional information, please contact:

Nanna Iversen

Chief Operating Officer

iversen@monsenso.com

+45 27267120


To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Participant Recruitment Begins for MENTBEST Research Project in Denmark

Participant Recruitment Begins for MENTBEST Research Project in Denmark

Copenhagen, Denmark 

We are excited to announce the launch of participant recruitment for the Danish arm of the European research project MENTBEST. The project is now seeking individuals to join a new study led by the Copenhagen Affective Disorder Research Center at Psychiatric Center Copenhagen, Region Hovedstadens Psykiatri.

About the Study

The aim of the study is to explore how a digital app can support individuals in managing depressive symptoms. As part of the larger MENTBEST initiative, this research trial will contribute to the development and validation of a personalised, AI-enabled self-care programme built on Monsenso’s digital health platform.

Who Can Participate?

We are looking for individuals who are currently experiencing depressive symptoms or who have previously been diagnosed with depression.

Common symptoms include:

  • Persistent sadness
  • Reduced interest or pleasure in activities
  • Lower energy levels
  • Difficulty concentrating or making decisions
  • Fatigue and disrupted sleep
  • Changes in appetite

If this sounds familiar and you are interested in contributing to mental health research, we would like to hear from you!

About MENTBEST

MENTBEST (Mental Health Best Practices) – a Horizon Europe project funded by European Commision – is aiming to develop innovative, community-based mental health interventions. It targets vulnerable populations across Europe who are at high risk of developing mental health challenges due to rapid societal change. The project spans five countries: Denmark, Germany, Spain, Ireland, and Greece, and brings together 14 expert organisations under the leadership of the European Alliance Against Depression (EAAD).

The project focuses on delivering scalable, digital, evidence-based tools to strengthen self-help and resilience in the face of mental health challenges. In Denmark, the trial is being conducted in partnership with Monsenso, a digital mental health company, and mental health researchers from Region Hovedstaden.

Contact Information

To participate or learn more, please contact:

Malene Schwarz Dyrehot
Project Nurse, CADIC
📞 +45 21 52 34 53
📧 pck-mentina.region-hovedstadens-psykiatri@regionh.dk

For updates and further information, follow the MENTBEST LinkedIn page.


 To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Personae Project Reaches First Recruitment Milestone in Denmark

Personae Project Reaches First Recruitment Milestone in Denmark

Copenhagen, Denmark 

We are delighted to announce an important milestone for the Personae project: On June 11, the first patient was enrolled in the Danish study at Center for Digital Psychiatry at Region South Denmark.

About the project

Personae is a research and innovation initiative supported by Innovation Fund Denmark. It develops and evaluates AI-enabled blended care for mental health by combining smartphone technology, patient-reported outcomes, and internet-based cognitive behavioural therapy (iCBT) to tailor treatment to the individual, with a particular focus on depression.

COLLABORATION

The study is led by the Copenhagen Affective Disorder Research Center (CADIC) at Psychiatric Center Copenhagen, Region Hovedstadens Psykiatri, in close collaboration with Monsenso, and brings together additional partners from Denmark and Ireland: the University of Limerick (D²iCE), the Centre for Innovative Medical Technology (CIMT), and Depressionsforeningen.

This first recruitment marks an exciting step forward in realising the project’s ambitions to deliver scalable, digital, evidence-based solutions that strengthen access to mental health care across Europe.

For more information about the project and its progress, visit the Personae website or follow Monsenso on LinkedIn.


 To learn more or explore a pilot or integration, book a demo or get in touch via our website.

Start of Patient Recruitment for the Phase V Project

Start of Patient Recruitment for the Phase V Project

Copenhagen, Denmark 

We are delighted to share an update on PhaseV, a national cross-sector innovation effort, supported by Innovation Fund Denmark, that aims at advancing decentralised, real-world clinical studies in Denmark.

ABOUT THE PROJECT

PhaseV is developing a new, digital model for running clinical studies that brings monitoring closer to patients and clinicians over longer periods. It collects patient-generated real-world data via questionnaires and connected devices, presenting insights to patients in an app and to clinicians in a web portal, both developed by Monsenso. The programme will pilot three proof-of-concept studies in obesity, diabetic foot ulcers, and chronic spontaneous urticaria.

Recruitment has begun for the obesity research arm of the PhaseV project

Steno Diabetes Center Aarhus is recruiting participants for a 24-week, fully online study. Participants receive personal guidance and support from clinical dietitians while data are gathered digitally at home using a smartwatch, connected scale, and the study app.

The primary objective of this study is to assess the feasibility of enrolling participants with overweight or obesity into weight management programs within a decentralised clinical trial (DCT) framework, and to evaluate the ability to reliably monitor body weight in such a setting. In addition to feasibility, the study seeks to determine whether relevant health gain parameters can be accurately captured by leveraging participant compliance data obtained through digital device usage. This approach aims to provide insight into both adherence and the quality of data collection in a decentralised environment. Another important objective is to investigate the impact of weight management interventions on health outcomes over the course of the study. By analysing longitudinal health data collected remotely, the research intends to evaluate the effectiveness of these programs in producing measurable improvements. Finally, the study includes an evaluation of participants’ reported satisfaction with the devices used, as well as their perspectives on the overall feasibility of the decentralised setup. Incorporating these user-reported outcomes ensures that the study not only addresses clinical effectiveness but also considers the practical and experiential dimensions of trial participation. Taken together, these objectives reflect a comprehensive effort to explore both the scientific and operational dimensions of conducting weight management research through decentralised clinical trial methodologies.

If the project may be relevant to citizens or patients you support (exclusively in Region Midtjylland), please share the project page and participation form

cross-sectorial COLLABORATION

The consortium is led by Monsenso and includes partners across academia, healthcare, industry, and innovation: Aarhus University, Research Unit for General Practice (FEAP), Bispebjerg Hospital, Steno Diabetes Center Aarhus, Aarhus Municipality, the Danish Technological Institute, the Alexandra Institute, the Copenhagen Institute for Futures Studies, Danish Life Science Cluster, Novo Nordisk, and Novartis.

PhaseV aims to deliver a scalable digital platform for effective decentralised recruitment, continuous data capture, and phase-V style real-world studies that can strengthen patient care and decision-making.

For more information about the project and its progress, visit the PhaseV website or the Danish Life Science Cluster project page, or follow Monsenso on LinkedIn.


 To learn more or explore a pilot or integration, book a demo or get in touch via our website.